CD274 and non-small cell lung carcinoma: In this large multicentre real-life cohort involving NSCLC patients with PD-L1 ≥ 50%, we observed that physicians were more likely to choose a first-line chemo-immunotherapy for younger patients, with symptomatic disease at diagnosis, multi-metastatic involvement, and/or with brain metastasis.